SCHEDULE: Point72 Discloses 7.8% Stake in Relay Therapeutics

Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen have disclosed a shared beneficial ownership of 7.8% in Relay Therapeutics, Inc.

Summary

• Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen collectively reported shared beneficial ownership of 13,445,704 shares of Relay Therapeutics, Inc. Common Stock.
• This ownership represents 7.8% of the outstanding class of Relay Therapeutics, Inc. Common Stock.
• The beneficial ownership is held through Point72 Associates, an investment fund managed by Point72 Asset Management, L.P.
• Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management, and Steven A. Cohen controls both entities.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported beneficial ownership position.
• The reporting persons have shared voting power and shared dispositive power over all 13,445,704 shares.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a reputable institutional investor like Point72 Asset Management and Steven A. Cohen is generally viewed positively by the market, suggesting a vote of confidence in the company.

Positives

• A significant stake by a prominent institutional investor like Point72 Asset Management and Steven A. Cohen may signal confidence in Relay Therapeutics, Inc.'s future prospects.
• The transparency of this disclosure provides clarity to the market regarding major shareholders.

Industry Context

This Schedule 13G filing is a standard disclosure required when an institutional investor acquires beneficial ownership of more than 5% of a company's voting class of securities. It provides transparency into significant ownership stakes, which can influence market perception and investor sentiment, particularly when the investor is a well-known entity like Point72 Asset Management.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially influencing investor confidence and trading decisions.
• Company Management: Awareness of a large, active institutional investor on the shareholder register.

Key Dates

Keywords

Relay Therapeutics, Point72 Asset Management, Steven A. Cohen, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, Common Stock, Biotechnology